Mutations in fibroblast growth factor receptors (Fgfrs) 1-3 cause skeletal disease syndromes in humans. Although these Fgfrs are expressed at various stages of chondrocyte and osteoblast development, their function in specific skeletal cell types is poorly understood. Using conditional inactivation of Fgfr1 in osteo-chondrocyte progenitor cells and in differentiated osteoblasts, we provide evidence that FGFR1 signaling is important for different stages of osteoblast maturation. Examination of osteogenic markers showed that inactivation of FGFR1 in osteo-chondroprogenitor cells delayed osteoblast differentiation, but that inactivation of FGFR1 in differentiated osteoblasts accelerated differentiation. In vitro osteoblast cultures recapitulated the in vivo effect of FGFR1 on stage-specific osteoblast maturation. In immature osteoblasts, FGFR1 deficiency increased proliferation and delayed differentiation and matrix mineralization, whereas in differentiated osteoblasts, FGFR1 deficiency enhanced mineralization. Furthermore, FGFR1 deficiency in differentiated osteoblasts resulted in increased expression of Fgfr3, a molecule that regulates the activity of differentiated osteoblasts. Mice lacking Fgfr1, either in progenitor cells or in differentiated osteoblasts, showed increased bone mass as adults. These data demonstrate that signaling through FGFR1 in osteoblasts is necessary to maintain the balance between bone formation and remodeling through a direct effect on osteoblast maturation.
Introduction
Mutations in FGFRs account for many of the craniosynostosis and chondrodysplasia syndromes in humans (Chen and Deng, 2005; Morriss-Kay and Wilkie, 2005; Ornitz, 2005; Ornitz and Marie, 2002) . Although the vast majority of mutations that cause craniosynostosis syndromes are associated with FGFR2, a single missense mutation in FGFR1 (P252R) can cause Pfeiffer syndrome and phenocopies several Pfeiffer syndrome mutations in FGFR2 (Schell et al., 1995) . The same mutation has also been identified in a single patient who presented with Jackson-Weiss syndrome (Roscioli et al., 2000) , a mild craniofacial syndrome. Other missense mutations in FGFR1 cause osteoglophonic dysplasia, a syndrome involving craniosynostosis, rhizomelic dwarfism and nonossifying bone lesions (White et al., 2005) . This genetic evidence establishes a role for FGFR1 in skeletal development and suggests that FGFR1, FGFR2 and FGFR3 signaling pathways may have similar or redundant functions. In addition to premature fusion of cranial sutures, several of the classic craniosynostosis syndromes have associated phenotypes that affect long bone development in the appendicular skeleton. For example, Pfeiffer syndrome patients have characteristic broad thumbs and toes, and Apert syndrome patients have soft tissue and bony syndactyly (Wilkie et al., 2002) . This suggests that FGFR1 and FGFR2 are important for early limb patterning and endochondral and intramembranous skeletal development.
Fgfrs 1-3 are expressed in the developing and mature skeleton in patterns suggestive of both unique and redundant function (Ornitz and Marie, 2002) . In the developing growth plate, both Fgfr1 and Fgfr2 are expressed in condensing mesenchyme that will give rise to cartilage. Fgfr2 remains expressed in reserve chondrocytes and appears to be down regulated in proliferating chondrocytes, whereas Fgfr1 is expressed in hypertrophic chondrocytes. Later in development, Fgfr1 and Fgfr2 are both expressed in the perichondrium and periosteum, tissues that give rise to osteoblasts and cortical bone. In contrast to Fgfr1 and Fgfr2, Fgfr3 is prominently expressed in proliferating chondrocytes where it regulates cell growth and differentiation and in differentiated osteoblasts where it regulates bone density and cortical thickness (Valverde-Franco et al., 2004; Xiao et al., 2004) .
Activating mutations in FGFR3 in humans and mice causes achondroplasia, whereas mice lacking Fgfr3 (Fgfr3 −/− ) showed skeletal overgrowth accompanied by increased chondrocyte proliferation and an expanded proliferating and hypertrophic chondrocyte zone (Chen et al., 1999; Colvin et al., 1996; Deng et al., 1996; Naski et al., 1998) . The skeletal overgrowth is thought to result from failure of the growth plate to fully close. As adults, Fgfr3 −/− mice were osteopenic, suggesting a role for FGFR3 signaling in differentiated, Fgfr3-expressing osteoblasts (Valverde-Franco et al., 2004) .
Mice lacking Fgfr2 (Fgfr2 −/− ) die at embryonic day 10.5 (E10.5), prior to skeletal development (Xu et al., 1998) . The contribution of FGFR2 signaling to skeletal development has been clarified to some extent by using splice form-specific knockouts and conditional gene deletion approaches in mice. These studies demonstrated that FGFR2 positively regulates bone growth and the anabolic function of osteoblasts. The resulting phenotype of mice lacking mesenchymal Fgfr2 included skeletal dwarfism, decreased bone density, incomplete formation of the dorsal vertebrae and tarsal joint fusion (Eswarakumar et al., 2002; Yu et al., 2003) .
Embryos lacking Fgfr1 (Fgfr1 −/− ) die shortly after gastrulation (Yamaguchi et al., 1994) , necessitating a conditional knockout approach to address function later in development. Although the contribution of Fgfr1 to specific skeletal lineages is not known, Fgfr1 has recently been shown to be important for early limb bud development and distal skeletal patterning. Fgfr1 is expressed in limb bud mesenchyme that gives rise to mesenchymal condensations and eventually to the chondrogenic and osteogenic lineage (Orr-Urtreger et al., 1991; Peters et al., 1992; Xu et al., 1999b) . Hypomorphic alleles of Fgfr1 or conditional inactivation of Fgfr1 prior to limb bud initiation affects digital patterning and the formation of some skeletal elements (Li et al., 2005; Partanen et al., 1998; Verheyden et al., 2005) . To address the role of FGFR1 signaling specifically in the osteo-chondrocyte lineage, we have conditionally inactivated Fgfr1 in osteo-chondro-progenitor cells and in differentiated osteoblasts. Here we provide in vivo and in vitro evidence that demonstrates multiple roles for FGFR1 signaling in endochondral bone growth and remodeling. We demonstrate that loss of signaling through FGFR1 results in a delay in terminal maturation of hypertrophic chondrocytes. In osteoblasts, we show that FGFR1 signaling differentially regulates osteoblast growth and differentiation depending on the stage of osteoblast maturation.
Materials and methods

Mice
The conditional allele for FGFR1 has been previously generated and characterized (Pirvola et al., 2002) . A null allele for FGFR1 (Fgfr1 Δ/+ ) was made by germline Cre-mediated excision of the floxed region of Fgfr1. Col2-Cre transgenic mice (Ovchinnikov et al., 2000) were used to inactivate Fgfr1 in the osteo-chondrocyte lineage. Mice heterozygous for an Fgfr1 null allele (Fgfr1 Δ/+ ) and heterozygous for Cre (Col2-Cre/+) were mated to mice homozygous for a floxed allele of Fgfr1 (Fgfr1
) with a genotype Fgfr1 flox/Δ ,Col2-Cre/+, were born with a normal Mendelian frequency. To selectively inactivate the floxed allele of Fgfr1 in differentiated osteoblasts, α1(I)-collagen-Cre (Col1-Cre) transgenic mice (Dacquin et al., 2002) were mated to either Fgfr1 flox/flox or Fgfr1 flox/Δ mice to yield Fgfr1
Col1-cko conditional knockout mice. Both genotype combinations were used for different experiments and both yielded similar phenotypes.
Osteoblast and osteoclast cell culture
Osteoblasts were derived from long bones following a protocol similar to that used by Declercq et al. (2004) . Briefly, femur and tibia from 1.5-to 3-month-old mice were separated from soft tissue, bone marrow was flushed out with PBS, and bones were washed several times in PBS. Bone chips were then incubated in α-minimal essential medium (α-MEM) containing 0.2 mg/ml bacterial collagenase (type 1, Sigma) for 30 min at 37°C with shaking. The medium was discarded and replaced with fresh medium containing collagenase and incubated for an additional 30 min. Released cells were collected after three collagenase digestions. Cells and digested bone pieces were collected by centrifugation and suspended in α-MEM containing 10% fetal bovine serum and antibiotics. Cells were then seeded onto 250 ml tissue culture flasks or 10 cm plates and allowed to proliferate to confluence. To measure cell proliferation, cells were trypsinized and 5000 cells were plated per well in a 96-well plate; medium was replaced with medium containing 3 H-thymidine (1 μCi/well) for 4 h before lysis and harvest on glass fiber filters. Mineralization medium contained 50 μg/ml ascorbic acid and 10 mM β-glycerophosphate.
Alkaline phosphatase activity in osteoblasts
Alkaline phosphatase enzymatic activity was measured using a colorimetric assay (Sigma FAST™-pNitrophenyl Phosphate tablets, N9389, Sigma) as described (Sugiyama et al., 2003) . 10,000 cells per well were plated in a 24-well plate.
Alizarin red staining of mineralized osteoblast cultures
Cell cultures were washed with PBS and then fixed in 70% ethanol for 1 h. After fixation, cells were washed with water and stained with 0.4% Alizarin red (Sigma) for 15 min. Cells were then washed with water, dehydrated with 70% ethanol and dried. Quantification of mineral content was performed as described (Murshed et al., 2005) . Bound dye was dissolved in 10% glacial acetic acid and measured at 405 nm.
β-Galactosidase staining β-Galactosidase staining was performed as previously described (Yu et al., 2003) on whole embryos or frozen sections.
In situ hybridization
Plasmids used to generate riboprobes for in situ hybridization were from the following sources: Ihh (A. McMahon); Pth1r and Opn (H. Kronenberg); Collagen X (B. Olson); Cbfa1/Runx2 (B. de Crombrugghe), Mmp9 (Z. Werb), Trap (Ek-Rylander et al., 1991) , Collagen I (Metsaranta et al., 1991) , Fgfr1 (Peters et al., 1992) . Radioactive in situ hybridization was performed on paraffin embedded tissue as previously described (Xu et al., 1999a) .
Immunohistochemistry
The following antibodies were used for immunostaining: FGFR1 (1:400, Santa Cruz), β-catenin (1:100, Santa Cruz), osteopontin (1:100, MPIIIB10, Department of Biological Sciences, University of Iowa, Iowa City). The secondary antibodies used in immunofluorescence staining were mouse anti rabbit (1:100, Chemicon), goat anti mouse (1:200, Chemicon).
Bone morphometric analysis
Bone volume was estimated by tracing diaphyseal or trabecular bone areas on photographed histological sections using Canvas X software. Cell numbers were counted within a box drawn over comparable trabecular regions of control and conditional knockout embryos.
RNA isolation, cDNA synthesis and qRT-PCR analysis RNA was isolated from three biological samples. Each sample consisted of one 250-ml tissue culture flask of long-bone-derived cells grown in mineralization media for 1-3 weeks. Total RNA was isolated from cell cultures or tissues using the RNAqueous™ kit (Ambion Inc.). Equal amounts of RNA were used to prepare cDNA with random hexamers and PCR amplification using the manufacturer's protocol (Invitrogen SuperScript™). qRT-PCR amplifications used the following set of primers:
Gapdh: F-5′-TGGCAAAGTGGAGATTGTTGCC-3′; R-5′-AAGATGGTGATGGGCTTCCCG-3′; mFgfr1IIIc: F-5′CACATCGAGGTGAACGGGAGTAAG-3′; and R-5′ CGCATCCTCAAAGGAGACATTCC-3′.
Fgfr2, Fgfr3 and ColI primers were as described (Chikazu et al., 2000; Mathy et al., 2003; Saghizadeh et al., 2005) . QRT-PCR analysis was performed using SYBR green (BioRad) and a BioRad iCycler. Standard PCR amplification conditions were as follows: Gadph: (30 cycles, 94°C for 1 min, 55°C for 1 min, 72°C for 1.50 min). RT-PCR primers to detect the Fgfr1 delta allele (Δ) were as described (Ohkubo et al., 2004) .
Bone mass measurements by dual energy x-ray absorptiometry Bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry (DEXA) on whole mice not including the head, and analyzed on a PIXImus mouse densitometer (LUNAR Corp., Madison, Wisconsin).
Results
Expression of Fgfr1 in developing bone
In developing long bones, Fgfr1 is expressed in hypertrophic chondrocytes, in the perichondrium and in the trabecular region (primary spongiosa). To identify the specific cell types that express FGFR1, histology and immunohistochemistry were used to identify both cuboidal and spindle-shaped osteoblasts and corresponding FGFR1-expressing cells. Cuboidal osteoblasts are large differentiated cells that produce an extracellular matrix, and spindle-shaped osteoblasts are thin quiescent cells that line bone trabeculae (Hoshi et al., 1999; Zhang et al., 2003) . At postnatal day 0 (P0), the trabecular region contained both large cuboidal cells and spindle-shaped cells . Similar to what was shown previously (Calvi et al., 2003; Glass et al., 2005; Mansukhani et al., 2005; Zhang et al., 2003) , both of these populations of cells express osteopontin and β-catenin (Figs. 1D-E′). Immunohistochemistry, with an antibody against the carboxy terminus of FGFR1, showed FGFR1 expression in a similar pattern to these osteoblast markers in both cuboidal and spindle-shaped osteoblasts (Figs. 1F and F′) , demonstrating that FGFR1 is expressed in different stages of osteoblast maturation.
Conditional inactivation of Fgfr1 in osteo-chondro-progenitor cell lineages
To address the role of FGFR1 in the chondrocyte and osteoblast lineages, a floxed allele of Fgfr1 (Trokovic et al., 2003) was targeted with a proα1(II) collagen-Cre (Col2-Cre) transgene (Ovchinnikov et al., 2000) . Type II collagen is an early marker of the mesenchymal condensation and, later in development, a specific marker for the chondrocyte lineage. Mating of Col2-Cre mice with ROSA26 reporter mice (R26R) (Soriano, 1999 ) activated β-galactosidase (β-gal) expression in both the chondrocyte and osteoblast lineages, but not in osteoclasts or bone marrow stroma ( Fig. 2A , and data not shown) (Ovchinnikov et al., 2000) .
To inactivate Fgfr1 in the osteo-chondrocyte lineage, Fgfr1 Δ/+ ,Col2-Cre/+ mice were mated to Fgfr1 flox/flox mice.
Conditional knockout mice (Fgfr1
Col2-cko ), born with a normal Mendelian frequency, were indistinguishable from wild-type littermates. Skeletal preparations of P0 mice revealed a rounded cranium but an otherwise normal appearing skeleton with no delay in the formation of ossification centers. The efficiency of Col2-Cre mediated Fgfr1 gene deletion was analyzed by RNA in situ hybridization. Histological sections of the femur of Fgfr1
Col2-cko embryos showed loss of Fgfr1 expression in hypertrophic chondrocytes and trace levels of expression in trabecular bone and in the periosteum (Figs. 2B and C), suggesting nearly complete inactivation of the Fgfr1 gene in skeletal lineages.
Defects in growth plate development in Fgfr1
Col2-cko mice
To examine the growth plate of Fgfr1 Col2-cko mice, histological sections were prepared from E16.5-18.5 limbs. At E16.4, femur and tibia sections showed a ∼60% increase (femur 58%, P = 0.0001, n = 6; tibia 68%, P = 0.0003, n = 5) in the height of the hypertrophic chondrocyte zone in Fgfr1
Col2-cko mice compared to littermate controls (Figs. 2D and E) . No significant change was observed in the proliferating or prehypertrophic regions. The increased size of the hypertrophic zone seen in Fgfr1
Col2-cko embryos could result from increased differentiation, increased cell size or decreased loss of cells at the chondro-osseous junction. Histological sections suggested that cell size was not affected by loss of FGFR1 signaling. To examine chondrocyte differentiation, the expression of the parathyroid hormone receptor (Pth1r) and Indian hedgehog (Ihh) was examined by in situ hybridization. Both of these genes are expressed in pre-hypertrophic chondrocytes and define the pool of cells that is committed to hypertrophy. Similar levels of expression of Pth1r and Ihh were observed in Fgfr1
Col2-cko and control growth plates at E16.5 and at E18.5, suggesting that the rate of chondrocyte differentiation was not significantly affected Delayed terminal differentiation of hypertrophic chondrocytes could also account for an increased hypertrophic chondrocyte zone. Type X collagen (ColX), a specific marker of the hypertrophic chondrocyte, was expressed at a similar intensity in both Fgfr1
Col2-cko and control growth plates at E16.5. However, in Fgfr1
Col2-cko growth plates, the area of expression was broader and ColX-positive cells were found ectopically located in the trabecular region (Figs. 3A and B) . This suggested that the degradation of hypertrophic chondrocytes was delayed. Osteopontin (Opn) is expressed in distal hypertrophic zone chondrocytes and in osteoblasts (Lian et al., 1993) . Opn expression at the chondro-osseous junction was significantly reduced in Fgfr1
Col2-cko embryos at E18.5 (Figs. 3C and D) . This suggested that maturation of hypertrophic chondrocytes and/or trabecular osteoblasts was delayed. The frequency of apoptotic cells (TUNEL labeling) in the distal hypertrophic regions was low at this stage of development but appeared similar in control and Fgfr1
Col2-cko growth plates (data not shown).
Vascular invasion of the hypertrophic zone is required for the influx of both osteoblasts and osteoclasts. Osteoclasts are necessary for cartilage matrix degradation, an initial step in bone marrow cavity formation. MMP9 and MMP13 are proteases that are required for this process Stickens et al., 2004; Vu et al., 1998) . Mmp9 is highly expressed in terminal hypertrophic chondrocytes, monocytes and in osteoclast/ chondroclasts. Mmp13 is expressed by terminal hypertrophic chondrocytes and osteoblasts. Mice lacking either Mmp9 or Mmp13 develop an expanded hypertrophic zone and Mmp9 and Mmp13 synergize with each other in this process (Stickens et al., 2004) . In Fgfr1
Col2-cko embryos at E18.5, in situ hybridization analysis showed that Mmp9 expression was reduced at the chondro-osseous junction (Figs. 3E and F) . This was and Mmp13 −/− mice (Stickens et al., 2004) .
Fgfr1 regulates osteoblast function but not cell fate specification
Cbfa1/Runx2 is a transcription factor required for chondrogenesis and osteogenesis. Cbfa1 is expressed in osteoprogenitor cells, prior to the earliest stages of ossification, in proliferating chondrocytes and in osteoblasts (Otto et al., 1997; Yoshida et al., 2002) . Histological analysis of E16.5 Fgfr1
Col2-cko femurs showed normal levels of Cbfa1 expression in chondrocytes and in periosteal and trabecular regions, indicating normal specification of the chondrocyte and osteoblast lineage (Figs. 3I and J) . Interestingly, expression of Type I collagen, a marker of differentiating osteoblasts, was reduced in Fgfr1
Col2-cko embryos (Figs. 3K and L), suggesting a delay in osteoblast differentiation or an anabolic deficit in the osteoblast. Osteocalcin (Oc), a marker of differentiated osteoblasts, was expressed at very low levels in both control and Fgfr1
Col2-cko embryos at this stage, and no difference in expression could be detected (data not shown). However, by postnatal day 14, Oc expression was reduced in the secondary ossification center of Fgfr1
Col2-cko mouse femurs (Supplementary Figs. 1E and F) . 
Conditional inactivation of Fgfr1 in the osteoblast compartment
To assess the function of Fgfr1 in differentiated osteoblasts that express type I collagen, an α1(I)-collagen-Cre (Col1-Cre) transgenic line (Dacquin et al., 2002 ) was used to selectively inactivate the floxed allele of Fgfr1. ColI-Cre transgenic mice, when crossed with a β-galactosidase reporter line (R26R), showed β-gal activity in the periosteum and trabecular region, indicating that Cre activity was restricted to differentiated osteoblasts (Fig. 4A) . Specificity of the Fgfr1 gene deletion was demonstrated by genomic PCR, which showed the presence of a deleted Fgfr1 allele (Fgfr1 Δ ) in bone but not kidney tissue from Fgfr1 flox/flox ,ColI-Cre/+ mice (Fig. 4B ). Immunohistochemical analysis of FGFR1 expression in trabecular bone also showed a reduction in FGFR1 staining intensity in Fgfr1 flox/Δ ,ColI-Cre/+ conditional knockout (Fgfr1 ColI-cko ) tissue compared to control tissue (Figs. 4C and D) . To further examine Fgfr1 gene inactivation in osteoblasts, cultured long-bone-derived osteoblasts were allowed to differentiate in vitro and were then analyzed for the Fgfr1 gene deletion. The Fgfr1
Δ allele was detected in osteoblast cultures derived from Fgfr1 ColI-cko mice but not in osteoclast cultures derived from the same mice (Fig. 4E) . RT-PCR analysis showed that mRNA containing the Cre-induced deletion was expressed in osteoblast cultures derived from Fgfr1
ColI-cko mice but not from control Fgfr1 flox/flox mice (Fig. 4F) . Interestingly, higher levels of Fgfr1 Δ were detected in osteoblasts that were induced to differentiate with dexamethasone, consistent with expression of Col1 in more differentiated osteoblasts.
Increased trabecular bone volume in Fgfr1
ColI-cko neonatal mice Histological sections, prepared from the femur and tibia of neonatal mice, showed increased trabecular bone volume and a decreased marrow space in Fgfr1
ColI-cko embryos (Figs. 5A and B). Morphometric analysis of histological sections showed a 54% increase in the trabecular bone volume/total volume ratio in neonatal Fgfr1
ColI-cko mice (Fig. 5C ). Examination of trabecular architecture showed decreased cartilage matrix and increased osteoid in Fgfr1
ColI-cko embryos. This suggested an 
5E and F). Morphometric analysis of Fgfr1
ColI-cko neonatal limbs showed a 52% reduction in the number of cuboidal-shaped osteoblasts in the trabecular region (Fig. 5D) . At high magnification, these osteoblasts appeared to have an increased cytoplasmic area compared to wild-type osteoblasts (data not shown).
The observed increased trabecular bone volume could result from a combination of either increased deposition of bone matrix or decreased degradation and remodeling of bone. Because osteoclasts are essential for the bone remodeling process and are required to maintain the bone marrow cavity, we examined osteoclast number and morphology in bones from neonatal Fgfr1
ColI-cko embryos by staining for tartrate-resistant acid phosphatase (TRAP) activity. The number of TRAPpositive osteoclasts in Fgfr1
ColI-cko embryos was similar to that in wild-type embryos, suggesting normal numbers of osteoclast ColI-cko osteoblasts increased the level of Fgfr1Δ expression. Gapdh expression was used as a control for cDNA synthesis and PCR amplification. A, C and D, 10× objective. progenitor cells (Figs. 5G and H) . However, in Fgfr1
ColI-cko embryos, TRAP-positive cells were smaller and more rounded, whereas in control embryos, these cells were larger, flattened and spread over bone spicules (Figs. 5G′ and H′) . Given that the Col1-Cre transgene showed no recombinase activity in cultured osteoclasts (Fig. 4E) , the observed morphologic defect in osteoclast differentiation is likely to be secondary to FGFR1-dependent activities in osteoblasts.
To assess the extent of osteoblast maturation in control and Fgfr1
ColI-cko embryos, we introduced the R26R reporter allele into this genetic background. β-Gal staining acts as a marker to identify differentiated osteoblasts that have expressed Col1-Cre. In Col1-Cre,R26R mice, β-gal staining can be detected by postnatal day 5 (P5) in trabecular zone osteoblasts (Dacquin et al., 2002) . Interestingly, whole-mount and histological sections of P0 femurs from Fgfr1 ColI-cko , R26R embryos showed an increase in the intensity of β-gal staining compared to that of femurs from Col1-Cre,Fgfr1 flox/+ ,R26R control embryos (Figs. 5I-L) . Because Col1-Cre should be inactivating, Fgfr1and activating R26R simultaneously only in differentiated osteoblasts, this observation suggests that differentiated osteoblasts lacking FGFR1 may enhance maturation of neighboring immature osteoblasts, thus increasing the number of cells expressing Cre recombinase. To further examine the affects of loss of FGFR1 on osteoblast maturation, we examined osteoblast maturation in vitro.
Osteoblast differentiation, in vitro
To examine the effect of FGFR1 on the ability of osteoblasts to differentiate in vitro, osteoblast cultures were prepared from the femur and tibia of 1.5-to 2-month-old wild-type and Fgfr1 conditional knockout mice. Osteoblast cultures prepared from Fgfr1
Col2-cko mice showed a 39% increase in the rate of proliferation compared to cultures prepared from control mice (Fig. 6A) . Furthermore, alkaline phosphatase activity was significantly lower in Fgfr1
Col2-cko -derived cultures (Fig. 6B ). These data suggest that FGFR1 signaling normally acts to inhibit proliferation and enhance commitment to the osteoblast lineage in osteo-chondro-progenitor cells. To assess the ability of FGFR1-deficient osteo-progenitor cells to differentiate and mineralize, cultures were treated with medium containing β-glycerophosphate and ascorbic acid. After three weeks in mineralization medium, mineralized bone nodules were identified by alizarin red staining. Consistent with delayed osteoblast maturation, Alizarin red binding was decreased by 3.3-fold in Fgfr1
Col2-cko cultures compared to control cultures (Figs. 6C-E) .
In contrast to cultures prepared from Fgfr1 Col2-cko mice, cultures prepared from the femur and tibia of 1.5-to 2-monthold Fgfr1
Col1-cko mice showed similar levels of alkaline phosphatase activity and no change in the rates of proliferation after one week in culture. These data suggest that differentiation of osteo-chondro-progenitor cells were not affected by Col1-Cre, consistent with Cre expression only in differentiated osteoblasts. However, when Fgfr1
Col1-cko cultures were placed in mineralization medium for three weeks, alizarin red staining showed significantly more intense staining than control cells (2.3-fold increase in alizarin red binding) (Figs. 6F-H) . These data indicate that once osteoblasts are induced to mature, inactivation of Fgfr1 can further enhance their differentiation.
Osteoblast cultures lacking Fgfr2 or Fgfr3 show decreased mineralization (Valverde-Franco et al., 2004 and data not shown). Fgfr3 −/− cultures also showed increased expression of Fgfr1 (Valverde-Franco et al., 2004) . Another mechanism by which FGFR1 signaling could regulate osteoblast maturation could be by regulating the expression of Fgfr2 and Fgfr3. We therefore examined the expression of Fgfr2 and Fgfr3 in Fgfr1
ColI-cko osteoblasts cultured under ossifying conditions. In cultures prepared from Fgfr1
Col2-cko mice, no significant change in the levels of expression of Fgfr2 and Fgfr3, but a significant decrease in the level of Col1 was observed (Fig. 6I) . In cultures prepared from Fgfr1
Col1-cko mice, an increased level of expression of Fgfr3 was observed (Fig. 6J) . This is consistent with FGFR3 acting in differentiated osteoblasts to stimulate mineralization (Valverde-Franco et al., 2004) .
Bone pathology during skeletal maturation
Histological analysis of the growth plate of P10 to P15 Fgfr1
Col1-cko animals showed a partial resolution of the trabecular bone overgrowth phenotype seen at earlier ages. However, the trabecular region remained disorganized with persistent islands of hypertrophic chondrocytes trapped within trabecular bone and vascular sinuses encroaching on the chondro-osseous junction (Figs. 7A and B) . By P10, both control and Fgfr1
Col1-cko bones showed normalized osteoclast morphology, with multinucleated osteoclasts attached and spread out over trabeculae (data not shown). Examination of histological sections of femur and tibia of eight-month-old Fgfr1
Col1-cko mice showed increased trabecular bone compared to age matched control mice (Figs. 7C and D) . Morphometric analysis of the femurs revealed a 3 ± 0.5-fold increase in the trabeculae bone volume compared to control mice (Fig. 7E) .
Histological analysis of femur and tibia sections of six month and older Fgfr1
Col2-cko mice showed increased cortical bone thickness compared to age-matched controls (Figs. 7F-H) ; however, the trabecular regions appeared normal. Radiological examination of Fgfr1
Col2-cko mice also showed increased cortical thickness of the femur and tibia (not shown). Consistent with increased cortical thickness, whole body bone mineral density (DEXA) was increased by 14% in female Fgfr1
Col2-cko mice compared to age matched controls (Fig. 7I) . Col2-cko compared to control mice (n = 5, WT; n = 6, CKO, *P = 0.02). A and B, 10×; C and D, 2.5×; F and G, 4×.
Discussion
Mutations in FGFR1 that cause Pfeiffer syndrome, JacksonWeiss syndrome and osteoglophonic dysplasia in humans (Roscioli et al., 2000; Schell et al., 1995; White et al., 2005) provide genetic evidence for a role for FGFR1 in skeletal development. To define the function of FGFR1 in chondrocytes and in early and late stages of osteoblast development, we have conditionally inactivated a floxed allele of Fgfr1 in osteochondro-progenitor cells using Col2-Cre and in differentiated osteoblasts using Col1-Cre. Fgfr1
Col2-cko mice developed defects in both chondrocytes and osteoblasts, whereas the phenotype of Fgfr1
Col1-cko mice was restricted to osteoblasts. Although Fgfr1
Col2-cko mice developed an expanded hypertrophic chondrocyte zone, the precise role for FGFR1 signaling in the hypertrophic chondrocyte cannot be determined from these experiments because Fgfr1 is expressed and inactivated in both chondrocytes and cells within the perichondrium and chondro-osseous junction. Nevertheless, the experiments shown here suggest that loss of FGFR1 signaling primarily affects hypertrophic chondrocytes by acting on the chondroosseous junction to limit mechanisms that degrade hypertrophic chondrocytes. For example, Fgfr1
Col2-cko mice had decreased expression of MMP9 and decreased numbers of osteoclasts at the chondro-osseous junction, which could delay the degradation of hypertrophic chondrocytes Vu et al., 1998) . Additionally, maturation of hypertrophic chondrocytes may also be delayed, as indicated by reduced expression of osteopontin. Interestingly, in mice in which Fgfr2 was inactivated in a similar pattern with Dermo1-Cre, the hypertrophic chondrocyte zone was decreased at later stages of development (P7 versus E16.5), and osteoclast numbers at the chondroosseous junction were increased (Eswarakumar et al., 2002; Yu et al., 2003) . Thus, although acting most potently at different stages of skeletal development, FGFR1 and FGFR2 appear to have opposite affects on distal growth plate development. This could be due to differential activation of FGFR1 and FGFR2 by FGF ligands, differences in the strength or downstream components of the FGFR signals, or expression of FGFR1 and FGFR2 at different stages of osteoblast and chondrocyte development.
Fgfr regulation of osteoblast proliferation and differentiation
Inactivation of FGFR1 in immature osteoblasts (Fgfr1
Col2-cko ) did not affect formation of osteoprogenitor cells, as indicated by normal levels of expression of Cbfa1, but did cause a delay in the maturation of osteoblasts, as shown by reduced expression of type 1 collagen and osteopontin. Consistent with this, osteoprogenitor cell cultures derived from cortical bone of Fgfr1
Col2-cko mice showed increased rates of proliferation and decreased differentiation (decreased alkaline phosphatase expression and delayed mineralization). These data suggest that FGFR1 signaling in the osteoprogenitor cell normally acts to suppress proliferation and stimulate differentiation (Fig. 8A) . In contrast, when Fgfr1
ColI-cko osteoblasts were cultured under ossifying conditions, they showed accelerated differentiation, demonstrating that in differentiated osteoblasts, FGFR1 functions to suppress differentiation (Fig. 8B) . Thus, FGFR1 signaling has stage-specific effects on osteoblast maturation.
Regulation of osteoclast activation by osteoblast-FGFR1 signaling
Osteoclasts must spread out and attach to bone matrix to carry out their normal catabolic function (Teitelbaum, 2000) . The observation that osteoclasts are smaller and not spread out over bone trabeculae in neonatal Fgfr1
ColI-cko mice correlated with the observed increase in trabecular bone volume. This phenotype supports the hypothesis that Fgfr1-deficient osteoblasts cannot maintain normal osteoclast activity during this developmental period. We therefore hypothesized that FGFR1 signaling through the osteoblast must be involved in the regulation of osteoclastogenic cytokine production. Consistent with this, preliminary data shows that Fgfr1
ColI-cko osteoblast cultures express less RANKL (receptor activator of NFκβ ligand) and are not able to support osteoclastogenesis in in vitro co-culture. Further experiments will explore the stage-specific role of FGFR signaling in undifferentiated and differentiated osteoblasts' ability to produce RANKL and other cytokines that regulate osteoclast activity.
FGF signaling regulates bone growth
Increased anabolic activity in Fgfr1
ColI-cko osteoblasts was supported by the observation of increased numbers of β-galpositive osteoblasts in Fgfr1
Col1-cko ;R26R embryos compared to ColI-Cre;R26R embryos. In contrast to mice lacking Fgfr1, mice lacking Fgfr2 or Fgfr3 became osteopenic as adults (Eswarakumar et al., 2002; Valverde-Franco et al., 2004; Yu et al., 2003) . Thus, signaling through FGFR2 and FGFR3 acts to enhance bone formation. Consistent with this activity, osteoblast cultures derived from Fgfr2
Col1-cko mice or cko osteoblasts in culture may be further enhanced by increased expression and activity of Fgfr3.
The FGF ligands that signal to FGFR1 in osteoblasts are not known; however, three FGFs (FGFs 2, 9 and 18) are likely candidates for this role. FGF9 and FGF18 are expressed in the perichondrium/periosteum, and mice lacking these FGFs show delayed ossification during mid-gestation skeletogenesis (Colvin et al., 1999; Liu et al., 2002; Ohbayashi et al., 2002) (I. Hung, DMO, unpublished data). FGF2 is expressed in periosteal cells and osteoblasts Sabbieti et al., 1999) and adult Fgf2 −/− mice showed a loss of trabecular bone volume; however, no skeletal dysmorphology was reported in neonatal Fgf2 −/− mice (Montero et al., 2000) . These observations suggest that FGFs 2, 9 and 18 may act alone or redundantly to regulate osteoblast activity and physiology and that FGFs 9 and 18 may constitute the predominant signals during embryonic development, whereas FGF2 may be more important during postnatal stages. Consistent with a role for FGF2 in more differentiated osteoblasts, bone marrow stromal cultures from Fgf2 −/− mice showed a significantly decreased ability to mineralize in vitro (Montero et al., 2000) . The phenotypic similarities in Fgf2 −/− mice and Fgfr3 −/− mice suggest that FGF2 may signal through FGFR3 in osteoblasts to enhance mineralization.
The increased formation of bone at early ages and the increased number and rate of mineralization of differentiated osteoblasts could lead to the observed increase in bone volume observed in older mice. Furthermore, because in older mice chondrogenesis is not an active process and osteoblasts have progressed towards maturity, similarities between adult Fgfr1
ColI-cko and Fgfr1 Col2-cko mice suggest that the predominant role for FGFR1 signaling in mature bone is to decrease anabolic activity and slow terminal differentiation (mineralization) of osteoblasts (Fig. 8B) . A component of this mechanism may be through suppression of FGFR3 expression.
